



MicroScan

Dried Panel Quality Control Procedural Manual

Applicable to the Following Panel Types:

For use with MicroScan Dried Gram Negative and Positive MIC/Combo, Dried Gram Negative and Positive Breakpoint Combo Panels.

The acceptability of the identification media and antimicrobial agents should be checked by testing organisms with known reactions and MIC ranges. The results for the recommended American Type Culture Collection (ATCC*) control organisms are included in this QC manual. Refer to the Dried Gram Negative or Dried Gram Positive Panel Procedural Manuals for directions on the interpretation of the identification media and antimicrobial agents.

*American Type Culture Collection, Manassas, VA USA

11/2025

REVISION RECORD

Rev.	Date	Affected Pages
A	May 2008	First printing
B	August 2009	Added Streamlined ID QC per CLSI document M50, removed TFG spec, updated streamlined ESBL wording and added IPU#2 panels. Deleted Pos MIC 20. Added catalog numbers to panel types missing catalog numbers.
C	July 2010	Added Neg Urine Combo Panel Type 60, Neg Urine Combo Panel Type 61, Neg Urine Combo Panel Type 62, Neg Breakpoint Combo Type 47, and Pos Combo Panel Type 34. Deleted Neg MIC Plus Type 4.
D	September 2011	Completed removal of QC ATCC 51755 vs TFG.
E	January 2014	Added: B1017-419, B1017-420, B1017-421, B1017-422, B1017-423 Removed: B1017-203A, B1017-204, B1017-205, B1017-207, B1017-300, B1017-304, B1017-307, B1017-312, B1017-313, B1017-315, B1017-400, B1017-402, B1017-405
F	May 2015	Added: B1017-424 , B1017-425 , B1017-426 , B1017-427, B1017-428 , B1017-429 , B1017-430 , B1017-431 , B1017-216 , B1017-217, and B1017-218. Updated nomenclature and Beckman Coulter labeling.
G	January 2016	Removed: B1017-308
H	May 2016	ATCC 49138 organism name change to <i>S. haliotis</i> . Updated DCB results for <i>E. coli</i> ATCC 25922 and <i>P. aeruginosa</i> ATCC 27853.
HA	April 2018	Added: B1017-434, B1017-435, B1017-436, B1017-437, B1017-438, B1017-432, B1017-433, B1017-219, B1017-220 and B1017-222. Removed: B1017-303, B1017-305, B1017-403, B1017-301, B1017-302, B1017-306, B1017-200, B1017-201, B1017-206, and B1017-210.
HB	May 2019	Added Neg MIC 56 (NM56)
HC	June 2019	Removed: B1017-401 and B1017-413
HD	October 2019	Added C48639 and C48640
HE	June 2020	Updated QC range for <i>P. aeruginosa</i> ATCC 27853 for Ciprofloxacin-S in panels B1017-432 and B1017-433. Removed: B1017-416 and B1017-417
HF	June 2021	Updated QC range for <i>S. aureus</i> , ATCC 29213 for Oxacillin in panel B1017-218.
HG	June 2022	Added: C89643, C89644 and C89645 panels. ESBL Screen QC range and footnote for <i>Klebsiella pneumoniae</i> , ATCC 700603 for Aztreonam, Cefotaxime, Cefpodoxime, Ceftazidime and Ceftriaxone, where applicable. Ertapenem/ATCC 27853 footnote for organism Quality Control testing, where applicable. Ceftazidime-Avibactam footnote for recommended QC strains for testing, where applicable. Removed: B1017-404 panel.
HH	September 2023	Updated QC range for <i>E. Coli</i> , ATCC 25218, for the NUC102 panel by removing ≤ symbol.
HJ	February 2024	Affected Pages: In Identification Media section, for Pos Panels, Updated INU to N/A for <i>E. faecalis</i> ATCC 29212 and <i>S. gallolyticus</i> ATCC 49147.
HK	November 2025	Added: D18443, D18444, D18445, D18446, D18447, D18448. Removed: B1017-202, B1017-209, B1017-406, B1017-408, B1017-411, B1017-419, B1017-420, B1017-421, B1017-425, B1017-426, B1017-427, B1017-428, B1017-430, B1017-437, and B1017-438.

Identification Media

1. Neg Panels

	<i>E. coli</i> ATCC ¹ 25922	<i>P. aeruginosa</i> ATCC 27853	<i>K. oxytoca</i> ATCC 49131	<i>P. vulgaris</i> ATCC 49132
GLU	+	-	+	+
SUC	-	-	+	+
SOR	V	-	+	-
RAF	-	-	+	-
RHA	+	-	+	-
ARA	+	-	+	-
INO	-	-	+	-
ADO	-	-	+	-
MEL	V	-	+	-
URE ³	-	V	V	V
H ₂ S	-	-	-	+
IND	+	-	+	+
LYS	+	-	+	-
ARG	-	+	-	-
ORN	+	-	-	-
TDA	-	-	-	+
ESC	-	-	+	V
VP	-	- ⁴	+	V
CIT	-	+	+	V
MAL	-	+	+	-
ONPG	+	-	+	-
TAR ³	- ⁵	V	V	V
ACE	-	+ ²	-	V
CET	-	+	-	-
OF/G ³	+	V	+	+
OF/B	Blue, Blue-Green, Green	Blue, Blue-Green	Blue, Blue-Green, Green	Blue, Blue-Green, Green
P ₄ ³	+	+	+	V
NIT ³	+	V	+	+
DCB	Gray to Yellow	Gray to Yellow-Gray	Yellow	N/A
Cl ₄	-	-	-	+
Fd ₆₄	-	+	-	N/A
Cf ₈ ³	V	+	V	V
K ₄ ³	V	+	V	N/A
To ₄ ³	-	-	-	N/A

1. American Type Culture Collection, Manassas, VA USA

2. May require 48 hours incubation.

3. Refer to the Additional Test Table for additional positive or negative reactions as needed for each biochemical.

4. *P. aeruginosa* ATCC 27853 may produce a pale pink color in VP after 18 hours of incubation which should be interpreted as negative.

5. A weak positive reaction may be obtained with *E. coli* ATCC 25922 if panels are incubated longer than 18 hours.

N/A = Not Applicable

V = Variable

NOTE: Quality Control organisms are selected to provide positive/negative reactions for all identification substrates. As a result, the organism identifications may vary from that stated in the QC chart. The acceptability of product performance should be determined by comparison of test results, not identification.

2. Pos Panels

	<i>S. aureus</i> ATCC ¹ 29213	<i>E. faecalis</i> ATCC 29212	<i>S. gallolyticus</i> ATCC 49147	<i>M. luteus</i> ³ ATCC 49732
CV	-	+	N/A	N/A
MS	+	+	+	-
NIT	+	-	-	N/A
NOV ²	-	N/A	-	N/A
PGR ²	-	-	-	N/A
IDX	+	N/A	N/A	-
VP	+	+	+	-
OPT ²	+	+	+	N/A
PHO	+	N/A	-	N/A
BE	-	+	+	N/A
PYR	N/A	+	-	N/A
ARG	+	+	-	N/A
PGT	+	+	+	-
URE	+ ⁴	-	-	N/A
MAN	+	+	+	-
LAC	+	N/A	+	-
TRE	N/A	+	+	-
MNS	N/A	+	+	-
NACL	N/A	+	-	N/A
SOR	N/A	+	-	N/A
ARA ²	N/A	-	-	N/A
RBS	N/A	+	-	N/A
INU	N/A	N/A	N/A	N/A
RAF	N/A	-	+	N/A
BAC ²	N/A	+	+	N/A
PRV	N/A	+	-	N/A
TFG	+	+	+	N/A

1. American Type Culture Collection, Manassas, VA USA
2. Refer to Additional Test Table for additional positive or negative reactions as needed for each biochemical.
3. *M. luteus* ATCC 49732 read on MicroScan instrumentation at 16-18 hours may show an N/R on the MIC section of the QC report. This has no impact on identification substrate Quality Control results at any read time.
4. May require 24 hour incubation.

N/A = Not Applicable

NOTE: Quality Control organisms are selected to provide positive/negative reactions for all identification substrates. As a result of this, the organism identifications may vary from that stated in the QC chart. The acceptability of product performance should be determined by comparison of test results, not identification.

Additional Test Table

1. Neg Panels

Organism	Substrate	Expected Result
<i>P. stuartii</i> ATCC 49809	URE	+
<i>P. putida</i> ATCC 49128	TAR	+
	NIT	-
	K ₄	-
<i>S. haliotis</i> ATCC 49138	OF/G	-
<i>E. faecalis</i> ATCC 29212	P ₄	-
<i>S. aureus</i> ATCC 29213	Cf ₈	-
<i>R. insidiosa</i> ATCC 49129	To ₄	+

2. Pos Panels

Organism	Substrate	Expected Result
<i>S. saprophyticus</i> ATCC 49907	NOV	+
<i>S. xylosum</i> ATCC 49148	PGR	+
<i>S. pneumoniae</i> ATCC 49136	OPT BAC	- -
<i>E. raffinosus</i> ATCC 49464	ARA	+

Streamlined QC*

1. Neg Panels

QC Organism	ATCC Number	Key Indicator Substrate	Expected Result	Out-of-Specification Result	Labile Substrate
<i>E. coli</i>	25922	ONPG	+	-	Yes
<i>E. coli</i>	25922	ARA	+	-	Yes

2. Pos Panels

QC Organism	ATCC Number	Key Indicator Substrate	Expected Result	Out-of-Specification Result	Labile Substrate
<i>S. gallolyticus</i>	49147	ARA	-	+	Yes

*Key indicators for Quality Control are provided for streamlined QC per CLSI document M50-A. Before implementing the streamlined QC program, refer to the M50-A document for details and check with applicable regulatory agencies and inspecting groups to confirm acceptance.

Antimicrobial Agents

1. *Control* - a control well is provided on each panel for reading of MICs by the autoSCAN-4 and WalkAway Systems.
2. *Growth* - a growth control well is provided on each panel to demonstrate how the organism will grow in the test medium without antimicrobial inhibition. If there is no growth in this well, the test must be repeated.
3. *Antimicrobial Dilutions* - the potency of the antimicrobial dilutions should be checked by testing organisms with known endpoints. Acceptable endpoint ranges for the recommended control organisms are listed on the following pages. Deterioration of an antimicrobial or other circumstances would result in MICs higher than the acceptable ranges.

Neg Urine Combo Panel Type 51 (B1017-407)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Cefazolin	Cfz	≤8	>16	N/A	N/A
Cefepime	Cpe	≤4	≤4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1, 4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤8	≤8->32	N/A	≥2
Cefuroxime	Crn	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤2	≤2->4 ⁶	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Moxifloxacin	Mxf	≤2	≤2->4 ⁶	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Ticarcillin-K Clavulanate	Tim	≤16/2	≤16/2,64/2	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

6. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg Urine Combo Panel Type 55 (B1017-409)

Antimicrobial Agents	Abbr.	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>E. coli</i>	<i>K. pneumoniae</i>
		ATCC 25922	ATCC 27853	ATCC 35218	ATCC 700603
		Range ^{1,2}	Range ^{1,2}	Range ^{1,2}	Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤8	≤8	N/A	≥2
Cefepime	Cpe	≤8	≤8	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefotetan	Ctn	≤16	>32	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤8	≤8,32->32	N/A	≥2
Cefuroxime	Crn	≤4-8	>16	N/A	N/A
Cephalothin	Cf	≤8-16	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤1	2->4 ⁶	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin	Pi	≤16	≤16	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

6. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg Urine Combo Panel Type 61 (B1017-414)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤8	>16	N/A	N/A
Cefepime	Cpe	≤4	≤4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1, 4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8, 32->32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤1	2->4 ⁶	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.

5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.

6. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg Urine Combo Panel Type 73 (B1017-423)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>4	N/A	N/A
Cefepime	Cpe	≤8	≤8	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1, 4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8, 32->32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Cephalothin	Cf	≤8-16	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁶	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Ticarcillin-K Clavulanate	Tim	≤16/2	≤16/2, 64/2	≤16/2	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim	T	≤8	>8	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

6. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg Urine Combo Panel Type 77 (B1017-429)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range^{1,2}	<i>E. coli</i> ATCC 35218 Range^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range^{1,2}
Amikacin	Ak	<16	<16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime-ESBL ³	CftE	≤1	N/A	N/A	>1
Cefotaxime ³	Cft	≤2	8-32	N/A	≥2
Ceftazidime ³	Caz	≤4	≤4	N/A	≥4
Ceftriaxone ³	Cax	≤1	8-≥32	N/A	≥2
Cefuroxime	Crn	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Doripenem	Dor	≤0.5	≤0.5	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁴	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	≥8	N/A	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg Urine Combo Panel Type 79 (B1017-431)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range^{1,2}	<i>E. coli</i> ATCC 35218 Range^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range^{1,2}
Amikacin	Ak	≤8	≤8	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Cefuroxime	Crm	≤2-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁶	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤0.5	≤0.5-1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin	Pi	≤16	≤16	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

6. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg Urine Combo 84 (B1017-434)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range^{1,2}	<i>E. coli</i> ATCC 35218 Range^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤4/2	>16/8	8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefotaxime-ESβL ³	CftE	≤1	N/A	N/A	>1
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8,32->32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁶	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Urine Combo 85 (B1017-435)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range^{1,2}	<i>E. coli</i> ATCC 35218 Range^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefotaxime-ESβL ³	CftE	≤1	N/A	N/A	>1
Cefotetan	Ctn	≤16	>32	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8,32->32	N/A	≥2
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁶	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Minocycline	Min	≤4	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Urine Combo 86 (B1017-436)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4
Ceftazidime-Avibactam ⁶	CZA	≤8/4	≤8/4	≤8/4 ⁷	≤8/4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8,32->32	N/A	≥2
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Urine Combo 89 (C48639)

Antimicrobial Agent	Abbr.	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>E. coli</i>	<i>K. pneumoniae</i>	<i>K. pneumoniae</i>
		ATCC 25922	ATCC 27853	ATCC 35218	ATCC 700603	ATCC BAA-1705
		Range ^{1,2}	Range ^{1,2}	Range ^{1,2}	Range ^{1,2}	Range ^{1,2}
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≥2	N/A
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4	N/A
Ceftazidime-Avibactam ⁶	CZA	≤4/4	≤4/4	≤4/4 ⁷	≤4/4	N/A
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8,32->32	N/A	≥2	N/A
Cefuroxime	Crm	≤4-8	>16	N/A	N/A	N/A
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A	N/A
Meropenem-Vaborbactam	MEV	N/A	≤4/8	N/A	N/A	≤4/8
Minocycline	Min	≤4	N/A	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A	N/A
Tobramycin	To	≤2	≤2	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
- N/A = Not Applicable

Neg Urine Combo 90 (C48640)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}	<i>K. pneumoniae</i> ATCC BAA-1705 Range ^{1,2}
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	≥16	N/A	≥2	N/A
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4	N/A
Ceftazidime-Avibactam ⁶	CZA	≤4/4	≤4/4	≤4/4 ⁷	≤4/4	N/A
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	>2	N/A	≥2	N/A
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A	N/A
Eravacycline	ERV	≤0.5	>0.5 ⁸	N/A	N/A	N/A
Ertapenem	Etp	≤0.5	≥2 ⁸	N/A	N/A	N/A
Gentamicin	Gm	≤4	≤4	N/A	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A	N/A
Meropenem-Vaborbactam	MEV	N/A	≤2/8	N/A	N/A	≤2/8
Nitrofurantoin	Fd	≤32	>64	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.

7. *E. coli* ATCC 35218 is not required for routine testing.

8. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg Urine Combo 101 (C89643)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}	<i>K. pneumoniae</i> ATCC BAA-1705 Range ^{1,2}
Ampicillin	Am	≤8	>16	N/A	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≥2	N/A
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1, 4-16	N/A	≥4	N/A
Ceftazidime-Avibactam ⁶	CZA	≤8/4	≤8/4	≤8/4 ⁷	≤8/4	N/A
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	>2	N/A	≥2	N/A
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A	N/A
Meropenem-Vaborbactam	MEV	N/A	≤2/8	N/A	N/A	≤2/8
Minocycline	Min	≤4	N/A	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A	N/A
Tobramycin	To	≤2	≤2	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Urine Combo 102 (C89644)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤4/2	>16/8	8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1, 4-16	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	>2	N/A	≥2
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁶	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tobramycin	To	≤2	≤2	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Urine Combo 103 (C89645)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1, 4-16	N/A	≥4
Ceftazidime-Avibactam ⁶	CZA	≤8/4	≤8/4	≤8/4 ⁷	≤8/4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	>2	N/A	≥2
Cefuroxime	Crn	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tobramycin	To	≤2	≤2	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Combo Panel Type 68 (B1017-422)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Cefazolin	Cfz	≤2-4	>4	N/A	N/A
Cefepime	Cpe	≤4	≤4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1, 4	N/A	≥4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8, 32->32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤0.5	2->2 ⁶	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Piperacillin-Tazobactam	P/T	≤16/4	≤16/4	≤16/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Tobramycin	To	≤4	≤4	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Combo 104 (D18444)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	N/A	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≤2, 16->16
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	4->16
Ceftazidime-Avibactam ⁶	CZA	≤8/4	≤8/4	≤8/4 ⁷	≤8/4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	>2	N/A	≥2
Cefuroxime	Crn	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tobramycin	To	≤1-2	≤1	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Combo 105 (D18445)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}	<i>K. pneumoniae</i> ATCC BAA-1705 Range ^{1,2}
Amikacin	Ak	≤4-8	≤4-8	N/A	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A	N/A
Cefepime	Cpe	N/A	≤2-4	N/A	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≤2, 16->16	N/A
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	4->16	N/A
Ceftazidime-Avibactam ⁶	CZA	≤8/4	≤8/4	≤8/4 ⁷	≤8/4	N/A
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A	N/A
Ceftolozane-Tazobactam	C/T	≤2/4	≤2/4	≤2/4 ⁷	≤2/4	N/A
Ceftriaxone ³	Cax	≤1	>2	N/A	2->2	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A	N/A
Meropenem-Vaborbactam	MEV	N/A	≤4/8	N/A	N/A	≤4/8
Nitrofurantoin	Fd	≤32	>64	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A	N/A
Tobramycin	To	≤1-2	≤1	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg Combo 106 (D18446)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	N/A	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≤2, 16->16
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	4->16
Ceftazidime-Avibactam ⁶	CZA	≤8/4	≤8/4	≤8/4 ⁷	≤8/4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	>2	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A
Minocycline	Min	≤2	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg MIC Panel Type 38 (B1017-412)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amikacin	Ak	≤4-8	≤4-8	N/A	N/A
Ampicillin	Am	≤2-8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefotetan	Ctn	≤16	>32	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1-4	N/A	≥2
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤4	8->32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Cephalothin	Cf	≤8-16	>16	N/A	N/A
Chloramphenicol	C	≤8	>16	N/A	N/A
Ciprofloxacin	Cp	≤0.5	≤0.5-1	N/A	N/A
Ertapenem	Etp	≤1	2->4 ⁶	N/A	N/A
Gentamicin	Gm	≤1-2	≤1-4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤1	≤1-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin	Pi	≤16	≤16	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Ticarcillin-K Clavulanate	Tim	≤8/2	≤8/2-32/2	≤8/2-16/2	N/A
Tigecycline	Tgc	≤1	N/A	N/A	N/A
Tobramycin	To	≤1-2	≤1	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg MIC Panel Type 45 (B1017-424)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range^{1,2}	<i>E. coli</i> ATCC 35218 Range^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤4/2-8/4	N/A	≤4/2-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤1/0.5-4/2	>16/8	8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime-ESBL ³	CftE	≤1	N/A	N/A	>1
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1-4	N/A	≥2
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8-≥32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁶	N/A	N/A
Gentamicin	Gm	≤1-2	≤1-4	N/A	N/A
Imipenem	Imp	≤0.5	1-4	N/A	N/A
Levofloxacin	Lvx	≤0.25	0.5-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin	Pi	≤16	≤16	N/A	N/A
Piperacillin-Tazobactam	P/T	≤4/4	≤4/4-8/4	≤4/4	N/A
Tetracycline	Te	≤4	≥8	N/A	N/A
Ticarcillin-K Clavulanate	Tim	≤8/2	≤8/2-32/2	≤8/2-16/2	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Tobramycin	To	≤1-2	≤1	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.

4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.

6. Organism intended for Quality Control testing only.

N/A = Not Applicable

Neg MIC 53 (B1017-432)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤4/2	>16/8	8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefotaxime-ESβL ³	CftE	≤1	N/A	N/A	>1
Cefoxitin	Cfx	≤8	>16	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4
Ceftazidime-Avibactam ⁶	CZA	≤4/4	≤4/4	≤4/4 ⁷	≤4/4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftolozane-Tazobactam	C/T	≤2/4	≤2/4	≤2/4 ⁷	≤2/4
Ceftriaxone ³	Cax	≤1	8->32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ciprofloxacin-S	Cp-S	≤0.06	0.12->0.5	N/A	N/A
Doripenem	Dor	≤0.5	≤0.5	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A
Levofloxacin	Lvx	≤2	≤2-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Minocycline	Min	≤4	N/A	N/A	N/A
Moxifloxacin	Mxf	≤2	≤2->4 ⁸	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tigecycline	Tgc	≤1	N/A	N/A	N/A
Tobramycin	To	≤2	≤2	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for Ceftazidime or Cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg MIC 54 (B1017-433)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range^{1,2}	<i>E. coli</i> ATCC 35218 Range^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤4/2-8/4	N/A	≤4/2-16/8	N/A
Ampicillin	Am	≤8	>16	N/A	N/A
Ampicillin-Sulbactam	A/S	≤1/0.5-4/2	>16/8	8/4->16/8	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2
Cefazolin	Cfz	≤2-4	>16	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A
Cefotaxime-ESβL ³	CftE	≤1	N/A	N/A	>1
Cefotetan	Ctn	≤16	>32	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4
Ceftazidime-Avibactam ⁶	CZA	≤4/4	≤4/4	≤4/4 ⁷	≤4/4
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A
Ceftriaxone ³	Cax	≤1	8->32	N/A	≥2
Cefuroxime	Crm	≤4-8	>16	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A
Ciprofloxacin-S	Cp-S	≤0.06	0.12->0.5	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A
Gentamicin	Gm	≤1-2	≤1-4	N/A	N/A
Imipenem	Imp	≤0.5	1-4	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A
Minocycline	Min	≤4	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A
Piperacillin-Tazobactam	P/T	≤4/4	≤4/4-8/4	≤4/4	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A
Tobramycin	To	≤1-2	≤1	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤2/38	>2/38	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥ 3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg MIC 56 (C42464)

Antimicrobial Agent	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}	<i>K. pneumoniae</i> ATCC BAA-1705 Range ^{1,2}
Amikacin	Ak	≤16	≤16	N/A	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A	N/A
Ampicillin-Sulbactam	A/S	≤4/2	>16/8	8/4->16/8	N/A	N/A
Aztreonam ³	Azt	≤4	≤4-8	N/A	≥2	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A	N/A
Cefepime	Cpe	≤2	≤2-4	N/A	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	8-32	N/A	≥2	N/A
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A	N/A
Cefotaxime-ESBL ³	CftE	≤1	N/A	N/A	>1	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	≥4	N/A
Ceftazidime-Avibactam ⁶	CZA	≤4/4	≤4/4	≤4/4 ⁷	≤4/4	N/A
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A	N/A
Ceftolozane-Tazobactam	C/T	≤2/4	≤2/4	≤2/4 ⁷	≤2/4	N/A
Ceftriaxone ³	Cax	≤1	8,≥32	N/A	≥2	N/A
Cefuroxime	Crm	≤4-8	>16	N/A	N/A	N/A
Ciprofloxacin	Cp	≤0.25	≤0.25-1	N/A	N/A	N/A
Ertapenem	Etp	≤0.5	>1 ⁸	N/A	N/A	N/A
Gentamicin	Gm	≤2	≤2-4	N/A	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A	N/A
Levofloxacin	Lvx	≤0.5	≤0.5-4	N/A	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A	N/A
Meropenem-Vaborbactam	MEV	N/A	≤2/8	N/A	N/A	≤2/8
Minocycline	Min	≤4	N/A	N/A	N/A	N/A
Moxifloxacin	Mxf	≤2	≤2->4 ⁸	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A	N/A
Tetracycline	Te	≤4	≥8	N/A	N/A	N/A
Tigecycline	Tgc	≤2	N/A	N/A	N/A	N/A
Tobramycin	To	≤2	≤2	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	>2/38	N/A	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥ 3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
 8. Organism intended for Quality Control testing only.
- N/A = Not Applicable

Neg MIC 65 (D18443)

Antimicrobial Agents	Abbr.	<i>E. coli</i> ATCC 25922 Range ^{1,2}	<i>P. aeruginosa</i> ATCC 27853 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>K. pneumoniae</i> ATCC 700603 Range ^{1,2}	<i>K. pneumoniae</i> ATCC BAA-1705 Range ^{1,2}
Amikacin	Ak	≤4-8	≤4-8	N/A	N/A	N/A
Amoxicillin-K Clavulanate	Aug	≤8/4	N/A	≤8/4-16/8	N/A	N/A
Ampicillin	Am	≤8	>16	N/A	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	>16/8	≤8/4->16/8	N/A	N/A
Aztreonam	Azt	≤4	≤4-8	N/A	≤4->16 ³	N/A
Cefazolin	Cfz	≤2-4	>16	N/A	N/A	N/A
Cefepime	Cpe	N/A	≤2-4	N/A	N/A	N/A
Cefotaxime ^{3,4,5}	Cft	≤2	16->16	N/A	≤2, 16->16	N/A
Cefotaxime-K Clavulanate ^{4,5}	Cft/CA	N/A	N/A	N/A	N/A	N/A
Cefoxitin	Cfx	≤8	>16	N/A	N/A	N/A
Ceftazidime ^{3,4,5}	Caz	≤1	≤1,4	N/A	4->16	N/A
Ceftazidime-Avibactam ⁶	CZA	≤4/4	≤4/4	≤4/4 ⁷	≤4/4	N/A
Ceftazidime-K Clavulanate ^{4,5}	Caz/CA	N/A	N/A	N/A	N/A	N/A
Ceftolozane-Tazobactam	C/T	≤2/4	≤2/4	≤2/4 ⁷	≤2/4	N/A
Ceftriaxone ³	Cax	≤1	8,>32	N/A	2,>32	N/A
Cefuroxime	Crn	≤4-8	>16	N/A	N/A	N/A
Ciprofloxacin	Cp	≤0.06	0.12-1	N/A	N/A	N/A
Ertapenem	Etp	≤0.5	>1	N/A	N/A	N/A
Gentamicin	Gm	≤1-2	≤1-4	N/A	N/A	N/A
Imipenem	Imp	≤1	≤1-4	N/A	N/A	N/A
Levofloxacin	Lvx	≤0.12	0.5->2	N/A	N/A	N/A
Meropenem	Mer	≤1	≤1	N/A	N/A	N/A
Meropenem-Vaborbactam	MEV	N/A	≤4/8	N/A	N/A	≤4/8
Minocycline	Min	≤1-2	N/A	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	>64	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	≤8/4	N/A	N/A
Tetracycline	Te	≤4	8->8	N/A	N/A	N/A
Tobramycin	To	≤1-2	≤1	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	>2/38	N/A	N/A	N/A

1. Range = Expected Value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. When using the ESBL screening function, this additional endpoint may be obtained with *K. pneumoniae* ATCC 700603.
 4. When using the ESBL confirmation function, a ≥3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *K. pneumoniae* ATCC 700603. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 5. When using the ESBL confirmation function, a <3 twofold concentration decrease in an MIC for both antimicrobial agents tested in combination with K. Clavulanate versus its MIC when tested alone may be obtained with *E. coli* ATCC 25922. Actual QC ranges for ceftazidime or cefotaxime with K. Clavulanate have not been established.
 6. The recommended QC strains for testing ceftazidime-avibactam on MicroScan panels are *P. aeruginosa* ATCC 27853 and *K. pneumoniae* ATCC 700603. Off scale QC results could occur on certain panels with *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603.
 7. *E. coli* ATCC 35218 is not required for routine testing.
- N/A = Not Applicable

Pos Combo Panel Type 33 (B1017-211)

Antimicrobial Agents	Abbr.	<i>E. faecalis</i> ATCC 29212 Range^{1,2}	<i>S. aureus</i> ATCC 29213 Range^{1,2}
Amoxicillin-K Clavulanate ³	Aug	≤4/2	≤4/2
Ampicillin	Am	≤2	≤2->8
Ampicillin-Sulbactam ⁴	A/S	≤8/4	≤8/4
Cefoxitin Screen ⁵	CfxS	N/A	≤4
Ceftriaxone	Cax	N/A	≤8
Ciprofloxacin	Cp	≤1	≤1
Clindamycin	Cd	4->4	≤0.5
Daptomycin	Dap	1-4	≤0.5-1
Erythromycin	E	1-4	≤0.5-1
Gentamicin	Gm	≤4->8	≤4
Gentamicin Synergy Screen ⁶	GmS	≤500	N/A
Inducible Clindamycin Test ⁷	ICd	N/A	≤4/0.5
Levofloxacin	Lvx	≤1-2	≤1
Linezolid	Lzd	≤1-4	≤1-4
Moxifloxacin	Mxf	≤0.5 ⁹	≤0.5
Nitrofurantoin	Fd	≤32	≤32
Oxacillin	Ox	>2	≤0.25-0.5
Penicillin	P	2	0.25, 2, 8->8
Rifampin	Rif	≤1	≤1
Streptomycin Synergy Screen ⁸	StS	≤1000	N/A
Synercid	Syn	2->2	≤0.5-1
Tetracycline	Te	≤4->8	≤4
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5
Vancomycin	Va	1-4	0.5-2

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. An additional endpoint of ≤4/2->4/2 may be obtained with *E. coli* ATCC 35218.

4. An additional endpoint of ≤8/4->16/8 may be obtained with *E. coli* ATCC 35218.

5. An additional endpoint of >4 may be obtained with *S. aureus* ATCC 43300.

6. An additional endpoint of >500 may be obtained with *E. faecalis* ATCC 51299.

7. An additional endpoint of >4/0.5 may be obtained with *S. aureus* ATCC BAA-977.

8. An additional endpoint of >1000 may be obtained with *E. faecalis* ATCC 51299.

9. Organism intended for Quality Control testing only.

N/A = Not Applicable

Pos Combo Panel Type 34 (B1017-214)

Antimicrobial Agents	Abbr.	<i>E. faecalis</i> ATCC 29212 Range ^{1,2}	<i>S. aureus</i> ATCC 29213 Range ^{1,2}
Amoxicillin-K Clavulanate ³	Aug	≤4/2	≤4/2
Ampicillin	Am	≤2	≤2->8
Ampicillin-Sulbactam ⁴	A/S	≤8/4	≤8/4
Cefazolin	Cfz	N/A	≤4
Cefoxitin Screen ⁵	CfxS	N/A	≤4
Ciprofloxacin	Cp	≤1	≤1
Clindamycin	Cd	4->4	≤0.5
Daptomycin	Dap	1-4	≤0.5-1
Erythromycin	E	1-4	≤0.5-1
Gentamicin	Gm	≤4->8	≤4
Gentamicin Synergy Screen ⁶	GmS	≤500	N/A
Inducible Clindamycin Test ⁷	ICd	N/A	≤4/0.5
Levofloxacin	Lvx	≤1-2	≤1
Linezolid	Lzd	≤1-4	≤1-4
Moxifloxacin	Mxf	≤0.5 ⁹	≤0.5
Nitrofurantoin	Fd	≤32	≤32
Oxacillin	Ox	>2	≤0.25-0.5
Penicillin	P	2	0.25, 2->8
Rifampin	Rif	≤1	≤1
Streptomycin Synergy Screen ⁸	StS	≤1000	N/A
Synercid	Syn	2->2	≤1
Tetracycline	Te	≤4->8	≤4
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5
Vancomycin	Va	1-4	0.5-2

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. An additional endpoint of ≤4/2->4/2 may be obtained with *E. coli* ATCC 35218.

4. An additional endpoint of ≤8/4->16/8 may be obtained with *E. coli* ATCC 35218.

5. An additional endpoint of >4 may be obtained with *S. aureus* ATCC 43300.

6. An additional endpoint of >500 may be obtained with *E. faecalis* ATCC 51299.

7. An additional endpoint of >4/0.5 may be obtained with *S. aureus* ATCC BAA-977.

8. An additional endpoint of >1000 may be obtained with *E. faecalis* ATCC 51299.

9. Organism intended for Quality Control testing only.

N/A = Not Applicable

Pos Combo Panel Type 43 (B1017-217)

Antimicrobial Agent	Abbr.	<i>E. faecalis</i> ATCC 29212 Range^{1,2}	<i>S. aureus</i> ATCC 29213 Range^{1,2}
Ampicillin	Am	≤2	≤2->8
Cefoxitin Screen ⁷	CfxS	N/A	≤4
Ceftaroline	Cpt	N/A	≤0.5
Ciprofloxacin	Cp	≤1	≤1
Clindamycin	Cd	4->4	≤0.5
Daptomycin	Dap	1-4	≤0.5-1
Erythromycin	E	1-4	≤0.5-1
Gentamicin	Gm	≤4->8	≤4
Gentamicin Synergy Screen ⁴	GmS	≤500	N/A
Inducible Clindamycin Test ⁶	ICd	N/A	≤4/0.5
Levofloxacin	Lvx	≤1-2	≤1
Linezolid	Lzd	≤1-4	≤1-4
Moxifloxacin	Mxf	≤0.5 ³	≤0.5
Nitrofurantoin	Fd	≤32	≤32
Oxacillin	Ox	>2	≤0.25-0.5
Penicillin	P	2	≥0.25
Rifampin	Rif	≤1	≤1
Streptomycin Synergy Screen ⁵	StS	≤1000	N/A
Synercid	Syn	≥2	≤1
Tetracycline	Te	≤4->8	≤4
Tigecycline	Tgc	≤0.25	≤0.25
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5
Vancomycin	Va	1-4	0.5-2

1. Range = Expected value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. Organism intended for Quality Control testing only.
 4. An additional endpoint of >500 may be obtained with *E. faecalis* ATCC 51299.
 5. An additional endpoint of >1000 may be obtained with *E. faecalis* ATCC 51299.
 6. An additional endpoint of >4/0.5 may be obtained with *S. aureus* ATCC BAA-977.
 7. An additional endpoint of >4 may be obtained with *S. aureus* ATCC 43300.
- N/A = Not Applicable

Pos Combo Panel Type 44 (B1017-218)

Antimicrobial Agent	Abbr.	<i>E. faecalis</i> ATCC 29212 Range ^{1,2}	<i>S. aureus</i> ATCC 29213 Range ^{1,2}
Amoxicillin-K Clavulanate ⁴	Aug	≤4/2	≤4/2
Ampicillin	Am	≤2	≤2->8
Ampicillin-Sulbactam ⁸	A/S	≤8/4	≤8/4
Azithromycin	Azi	N/A	≤2
Cefazolin	Cfz	N/A	≤8
Cefoxitin Screen ⁹	CfxS	N/A	≤4
Ceftaroline	Cpt	N/A	≤0.5
Chloramphenicol	C	≤8	≤8-16
Ciprofloxacin	Cp	≤1	≤1
Clindamycin	Cd	>2	≤0.25-0.5
Daptomycin	Dap	≤1,4	≤1
Erythromycin	E	1-4	≤0.5-1
Gentamicin	Gm	≤4->8	≤4
Gentamicin Synergy Screen ⁵	GmS	≤500	N/A
Inducible Clindamycin Test ⁷	ICd	N/A	≤4/0.5
Levofloxacin	Lvx	≤1-2	≤1
Linezolid	Lzd	≤2-4	≤2-4
Moxifloxacin	Mxf	≤0.5 ³	≤0.5
Nitrofurantoin	Fd	≤32	≤32
Oxacillin	Ox	>2	≤0.25,1
Penicillin	P	2	≥0.25
Rifampin	Rif	≤1	≤1
Streptomycin Synergy Screen ⁶	StS	≤1000	N/A
Synercid	Syn	≥2	≤0.5-1
Tetracycline	Te	≤4->8	≤4
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5
Vancomycin	Va	1-4	≤0.5-2

1. Range = Expected value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. Organism intended for Quality Control testing only.
 4. An additional endpoint of ≤4/2->4/2 may be obtained with *E. coli* ATCC 35218.
 5. An additional endpoint of >500 may be obtained with *E. faecalis* ATCC 51299.
 6. An additional endpoint of >1000 may be obtained with *E. faecalis* ATCC 51299.
 7. An additional endpoint of >4/0.5 may be obtained with *S. aureus* ATCC BAA-977.
 8. An additional endpoint of ≤8/4->16/8 may be obtained with *E. coli* ATCC 35218.
 9. An additional endpoint of >4 may be obtained with *S. aureus* ATCC 43300.
- N/A = Not Applicable

Pos Combo Panel Type 45 (B1017-219)

Antimicrobial Agent	Abbr.	<i>E. faecalis</i> ATCC 29212 Range ^{1,2}	<i>S. aureus</i> ATCC 29213 Range ^{1,2}	<i>E. faecalis</i> ATCC 51299 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>S. aureus</i> ATCC 43300 Range ^{1,2}	<i>S. aureus</i> ATCC BAA-977 Range ^{1,2}
Amoxicillin-K Clavulanate	Aug	≤4/2	≤4/2	N/A	≤4/2->4/2	N/A	N/A
Ampicillin	Am	≤2	≤2,8->8	N/A	N/A	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	≤8/4	N/A	≤8/4->16/8	N/A	N/A
Azithromycin	Azi	N/A	≤2	N/A	N/A	N/A	N/A
Cefazolin	Cfz	N/A	≤8	N/A	N/A	N/A	N/A
Cefoxitin Screen	CfxS	N/A	≤4	N/A	N/A	>4	N/A
Ceftaroline	Cpt	N/A	≤0.5	N/A	N/A	N/A	N/A
Ceftriaxone	Cax	N/A	≤8	N/A	N/A	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A	N/A	N/A
Clindamycin	Cd	4->4	≤0.5	N/A	N/A	N/A	N/A
Daptomycin	Dap	≤1,4	≤1	N/A	N/A	N/A	N/A
Erythromycin	E	1-4	≤0.25-1	N/A	N/A	N/A	N/A
Gentamicin	Gm	≤4->8	≤4	N/A	N/A	N/A	N/A
Gentamicin Synergy Screen	GmS	≤500	N/A	>500	N/A	N/A	N/A
Inducible Clindamycin Test	ICd	N/A	≤4/0.5	N/A	N/A	N/A	>4/0.5
Levofloxacin	Lvx	≤1-2	≤1	N/A	N/A	N/A	N/A
Linezolid	Lzd	≤2-4	≤2-4	N/A	N/A	N/A	N/A
Meropenem	Mer	≤4-8	≤4	N/A	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	≤32	N/A	N/A	N/A	N/A
Oxacillin	Ox	>2	≤0.25-0.5	N/A	N/A	N/A	N/A
Penicillin	P	2	2,8->8	N/A	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤4/4	≤4/4	N/A	N/A	N/A	N/A
Rifampin	Rif	≤1	≤1	N/A	N/A	N/A	N/A
Streptomycin Synergy Screen	StS	≤1000	N/A	>1000	N/A	N/A	N/A
Tetracycline	Te	≤4->8	≤4	N/A	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5	N/A	N/A	N/A	N/A
Vancomycin	Va	1-4	≤0.5-2	N/A	N/A	N/A	N/A

1. Range = Expected value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

N/A = Not Applicable

Pos Combo Panel Type 46 (B1017-220)

Antimicrobial Agent	Abbr.	<i>E. faecalis</i> ATCC 29212 Range ^{1,2}	<i>S. aureus</i> ATCC 29213 Range ^{1,2}	<i>E. faecalis</i> ATCC 51299 Range ^{1,2}	<i>E. coli</i> ATCC 35218 Range ^{1,2}	<i>S. aureus</i> ATCC 43300 Range ^{1,2}	<i>S. aureus</i> ATCC BAA-977 Range ^{1,2}
Amoxicillin-K Clavulanate	Aug	≤4/2	≤4/2	N/A	≤4/2->4/2	N/A	N/A
Ampicillin	Am	≤2	≤2,8->8	N/A	N/A	N/A	N/A
Cefazolin	Cfz	N/A	≤8	N/A	N/A	N/A	N/A
Cefepime	Cpe	16->16	≤8	N/A	N/A	N/A	N/A
Cefotaxime	Cft	N/A	≤8	N/A	N/A	N/A	N/A
Cefoxitin Screen	CfxS	N/A	≤4	N/A	N/A	>4	N/A
Ceftaroline	Cpt	N/A	≤1	N/A	N/A	N/A	N/A
Cefuroxime	Crm	N/A	≤8	N/A	N/A	N/A	N/A
Clindamycin	Cd	>2	≤0.5	N/A	N/A	N/A	N/A
Daptomycin	Dap	1-4	≤0.5-1	N/A	N/A	N/A	N/A
Erythromycin	E	1-4	≤0.25-1	N/A	N/A	N/A	N/A
Gentamicin	Gm	≤4->8	≤4	N/A	N/A	N/A	N/A
Gentamicin Synergy Screen	GmS	≤500	N/A	>500	N/A	N/A	N/A
Inducible Clindamycin Test	ICd	N/A	≤4/0.5	N/A	N/A	N/A	>4/0.5
Levofloxacin	Lvx	≤1-2	≤1	N/A	N/A	N/A	N/A
Linezolid	Lzd	≤2-4	≤2-4	N/A	N/A	N/A	N/A
Meropenem	Mer	≤4-8	≤4	N/A	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	≤32	N/A	N/A	N/A	N/A
Oxacillin	Ox	>2	≤0.25,1	N/A	N/A	N/A	N/A
Penicillin	P	2	0.25,2,8->8	N/A	N/A	N/A	N/A
Rifampin	Rif	≤1	≤1	N/A	N/A	N/A	N/A
Streptomycin Synergy Screen	StS	≤1000	N/A	>1000	N/A	N/A	N/A
Synercid	Syn	2->2	≤1	N/A	N/A	N/A	N/A
Tetracycline	Te	≤4->8	≤4	N/A	N/A	N/A	N/A
Tigecycline ³	Tgc	≤0.25	≤0.25	N/A	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5	N/A	N/A	N/A	N/A
Vancomycin	Va	1-4	≤0.5-2	N/A	N/A	N/A	N/A

1. Range = Expected value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. The MicroScan Gram Positive panel does not include the full CLSI/FDA-recommended dilution ranges for QC testing of tigecycline.

N/A = Not Applicable

Pos Combo 50 (D18447)

Antimicrobial Agents	Abbr.	<i>E. faecalis</i> ATCC 29212 Range ^{1,2}	<i>S. aureus</i> ATCC 29213 Range ^{1,2}	<i>E. faecalis</i> ATCC 51299 Range ^{1,2}	<i>S. aureus</i> ATCC 43300 Range ^{1,2}	<i>S. aureus</i> ATCC BAA-977 Range ^{1,2}
Ampicillin	Am	≤0.25,8	0.5,>8	N/A	N/A	N/A
Azithromycin	Azi	N/A	≤2	N/A	N/A	N/A
Cefoxitin Screen	CfxS	N/A	≤4	N/A	>4	N/A
Ceftaroline	Cpt	N/A	≤0.5	N/A	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A	N/A
Clindamycin	Cd	>2	≤0.25-0.5	N/A	N/A	N/A
Daptomycin	Dap	≤1-4	≤1	N/A	N/A	N/A
Erythromycin	E	1-4	≤0.25-1	N/A	N/A	N/A
Gentamicin	Gm	≤4->8	≤4	N/A	N/A	N/A
Gentamicin Synergy Screen	GmS	≤500	N/A	>500	N/A	N/A
Inducible Clindamycin	ICd	N/A	≤4/0.5	N/A	N/A	>4/0.5
Levofloxacin	Lvx	≤1-2	≤1	N/A	N/A	N/A
Linezolid	Lzd	≤2-4	≤2-4	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	≤32	N/A	N/A	N/A
Oxacillin	Ox	4->4	≤0.25-0.5	N/A	N/A	N/A
Penicillin	P	0.5-2	0.25->8	N/A	N/A	N/A
Rifampin	Rif	≤1	≤1	N/A	N/A	N/A
Streptomycin Synergy Screen	StS	≤1000	N/A	>1000	N/A	N/A
Tetracycline	Te	4->8	≤2	N/A	N/A	N/A
Tigecycline	Tgc	≤0.25	≤0.25	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5	N/A	N/A	N/A
Vancomycin	Va	1-4	≤0.5-2	N/A	N/A	N/A

1. Range = Expected value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

N/A = Not Applicable.

Pos MIC Panel Type 29 (B1017-212)

Antimicrobial Agents	Abbr.	<i>E. faecalis</i> ATCC 29212 Range^{1,2}	<i>S. aureus</i> ATCC 29213 Range^{1,2}
Amoxicillin-K Clavulanate ⁴	Aug	≤4/2	≤4/2
Ampicillin	Am	≤2	≤2->8
Ampicillin-Sulbactam ⁵	A/S	≤8/4	≤8/4
Cefazolin	Cfz	N/A	≤4
Cefoxitin Screen ⁶	CfxS	N/A	≤4
Ceftriaxone	Cax	N/A	≤4
Chloramphenicol	C	≤8	≤8-16
Ciprofloxacin	Cp	≤1	≤1
Clindamycin	Cd	4->4	≤0.25-0.5
Daptomycin	Dap	1-4	≤0.25-1
Erythromycin	E	1-4	≤0.25-1
Gentamicin	Gm	4->8	≤1 ³
Gentamicin Synergy Screen ⁷	GmS	≤500	N/A
Imipenem	Imp	≤4	≤4
Inducible Clindamycin Test ⁸	ICd	N/A	≤4/0.5
Levofloxacin	Lvx	≤0.5-2	≤0.5
Linezolid	Lzd	1-4	1-4
Meropenem	Mer	≤2-8	≤2
Moxifloxacin	Mxf	≤0.5 ¹⁰	≤0.5
Nitrofurantoin	Fd	≤32	≤32
Oxacillin	Ox	>2	≤0.25-0.5
Penicillin	P	0.5-2	≥0.25
Rifampin	Rif	≤1	≤1
Streptomycin Synergy Screen ⁹	StS	≤1000	N/A
Synercid	Syn	2->2	≤0.25-1
Tetracycline	Te	4->8	≤1
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5
Vancomycin	Va	1-4	0.5-2

1. Range = Expected Value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. Gentamicin should be considered in control with PROMPT[®] Inoculation System if Gentamicin MIC is ≤1-2 µg/mL.

4. An additional endpoint of ≤4/2->4/2 may be obtained with *E. coli* ATCC 35218.

5. An additional endpoint of ≤8/4->16/8 may be obtained with *E. coli* ATCC 35218.

6. An additional endpoint of >4 may be obtained with *S. aureus* ATCC 43300.

7. An additional endpoint of >500 may be obtained with *E. faecalis* ATCC 51299.

8. An additional endpoint of >4/0.5 may be obtained with *S. aureus* ATCC BAA-977.

9. An additional endpoint of >1000 may be obtained with *E. faecalis* ATCC 51299.

10. Organism intended for Quality Control testing only.

N/A = Not Applicable

Pos MIC Panel Type 34 (B1017-216)

Antimicrobial Agent	Abbr.	<i>E. faecalis</i> ATCC 29212 Range ^{1,2}	<i>S. aureus</i> ATCC 29213 Range ^{1,2}
Ampicillin	Am	≤2	≤2->8
Cefazolin	Cfz	N/A	≤4
Cefoxitin Screen ⁸	CfxS	N/A	≤4
Ceftaroline	Cpt	N/A	≤0.5
Ceftriaxone	Cax	N/A	≤4
Chloramphenicol	C	≤8	≤8-16
Ciprofloxacin	Cp	≤1	≤1
Clindamycin	Cd	4->4	≤0.25-0.5
Daptomycin	Dap	1-4	≤0.25-1
Erythromycin	E	1-4	≤0.25-1
Gentamicin	Gm	4->8	≤1 ³
Gentamicin Synergy Screen ⁴	GmS	≤500	N/A
Inducible Clindamycin Test ⁷	ICd	N/A	≤4/0.5
Levofloxacin	Lvx	≤0.5-2	≤0.5
Linezolid	Lzd	1-4	1-4
Moxifloxacin	Mxf	≤0.25-0.5 ⁶	≤0.25
Nitrofurantoin	Fd	≤32	≤32
Oxacillin	Ox	>2	≤0.25-0.5
Penicillin	P	0.5-2	≥0.25
Rifampin	Rif	≤1	≤1
Streptomycin Synergy Screen ⁵	StS	≤1000	N/A
Synercid	Syn	≥2	≤0.25-1
Tetracycline	Te	4->8	≤2
Tigecycline	Tgc	≤0.12	≤0.12-0.25
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5
Vancomycin	Va	1-4	0.5-2

1. Range = Expected value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. Gentamicin should be considered in control with the PROMPT[®] Inoculation System if Gentamicin MIC is ≤1-2 µg/mL.

4. An additional endpoint of >500 may be obtained with *E. faecalis* ATCC 51299.

5. An additional endpoint of >1000 may be obtained with *E. faecalis* ATCC 51299.

6. Organism intended for Quality Control testing only.

7. An additional endpoint of >4/0.5 may be obtained with *S. aureus* ATCC BAA-977.

8. An additional endpoint of >4 may be obtained with *S. aureus* ATCC 43300.

N/A = Not Applicable

Pos MIC Panel Type 38 (B1017-222)

Antimicrobial Agent	Abbr.	<i>E. faecalis</i> ATCC 29212 Range^{1,2}	<i>S. aureus</i> ATCC 29213 Range^{1,2}	<i>E. faecalis</i> ATCC 51299 Range^{1,2}	<i>E. coli</i> ATCC 35218 Range^{1,2}	<i>S. aureus</i> ATCC 43300 Range^{1,2}	<i>S. aureus</i> ATCC BAA-977 Range^{1,2}
Amoxicillin-K Clavulanate	Aug	≤4/2	≤4/2	N/A	≤4/2- >4/2	N/A	N/A
Ampicillin	Am	≤2	≤2,8->8	N/A	N/A	N/A	N/A
Ampicillin-Sulbactam	A/S	≤8/4	≤8/4	N/A	≤8/4->16/8	N/A	N/A
Azithromycin	Azi	N/A	≤2	N/A	N/A	N/A	N/A
Cefazolin	Cfz	N/A	≤8	N/A	N/A	N/A	N/A
Cefepime	Cpe	16->16	≤4	N/A	N/A	N/A	N/A
Cefotaxime	Cft	N/A	≤8	N/A	N/A	N/A	N/A
Cefoxitin Screen	CfxS	N/A	≤4	N/A	N/A	>4	N/A
Ceftaroline	Cpt	N/A	≤0.5	N/A	N/A	N/A	N/A
Ceftriaxone	Cax	N/A	≤4	N/A	N/A	N/A	N/A
Cephalothin	Cf	N/A	≤8	N/A	N/A	N/A	N/A
Ciprofloxacin	Cp	≤1	≤1	N/A	N/A	N/A	N/A
Clindamycin	Cd	4->4	≤0.25-0.5	N/A	N/A	N/A	N/A
Daptomycin	Dap	1-4	≤0.5-1	N/A	N/A	N/A	N/A
Erythromycin	E	1-4	≤0.25-1	N/A	N/A	N/A	N/A
Gentamicin	Gm	≤4->8	≤4	N/A	N/A	N/A	N/A
Gentamicin Synergy Screen	GmS	≤500	N/A	>500	N/A	N/A	N/A
Imipenem	Imp	≤4	≤4	N/A	N/A	N/A	N/A
Inducible Clindamycin	ICd	N/A	≤4/0.5	N/A	N/A	N/A	>4/0.5
Levofloxacin	Lvx	≤1-2	≤1	N/A	N/A	N/A	N/A
Linezolid	Lzd	≤1-4	≤1-4	N/A	N/A	N/A	N/A
Meropenem	Mer	≤2-8	≤2	N/A	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	≤32	N/A	N/A	N/A	N/A
Oxacillin	Ox	>2	≤0.25-0.5	N/A	N/A	N/A	N/A
Penicillin	P	0.5-2	0.25->2	N/A	N/A	N/A	N/A
Piperacillin-Tazobactam	P/T	≤8/4	≤8/4	N/A	N/A	N/A	N/A
Rifampin	Rif	≤1	≤1	N/A	N/A	N/A	N/A
Streptomycin Synergy Screen	StS	≤1000	N/A	>1000	N/A	N/A	N/A
Synercid	Syn	2->2	≤0.5-1	N/A	N/A	N/A	N/A
Tetracycline	Te	≤4->8	≤4	N/A	N/A	N/A	N/A
Tigecycline ³	Tgc	≤0.25	≤0.25	N/A	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5	N/A	N/A	N/A	N/A
Vancomycin	Va	1-4	0.5-2	N/A	N/A	N/A	N/A

1. Range = Expected value (µg/mL)
 2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.
 3. The MicroScan Gram Positive panel does not include the full CLSI/FDA-recommended dilution ranges for QC testing of tigecycline.
- N/A = Not Applicable

Pos MIC 41 (D18448)

Antimicrobial Agents	Abbr.	<i>E. faecalis</i> ATCC 29212 Range ^{1,2}	<i>S. aureus</i> ATCC 29213 Range ^{1,2}	<i>E. faecalis</i> ATCC 51299 Range ^{1,2}	<i>S. aureus</i> ATCC 43300 Range ^{1,2}	<i>S. aureus</i> ATCC BAA-977 Range ^{1,2}
Ampicillin	Am	≤0.25-1	0.5->8	N/A	N/A	N/A
Azithromycin	Azi	N/A	≤0.5-2	N/A	N/A	N/A
Cefoxitin Screen	CfxS	N/A	≤4	N/A	>4	N/A
Ceftaroline	Cpt	N/A	≤0.25-0.5	N/A	N/A	N/A
Chloramphenicol	C	≤8	≤8-16	N/A	N/A	N/A
Ciprofloxacin	Cp	≤0.5-1	≤0.5	N/A	N/A	N/A
Clindamycin	Cd	4->4	≤0.25-0.5	N/A	N/A	N/A
Daptomycin	Dap	1-4	≤0.5-1	N/A	N/A	N/A
Erythromycin	E	1-4	≤0.25-1	N/A	N/A	N/A
Gentamicin	Gm	4->8	≤1 ³	N/A	N/A	N/A
Gentamicin Synergy Screen	GmS	≤500	N/A	>500	N/A	N/A
Inducible Clindamycin	ICd	N/A	≤4/0.5	N/A	N/A	>4/0.5
Levofloxacin	Lvx	≤0.5-2	≤0.5	N/A	N/A	N/A
Linezolid	Lzd	1-4	1-4	N/A	N/A	N/A
Moxifloxacin	Mxf	≤0.5	≤0.5	N/A	N/A	N/A
Nitrofurantoin	Fd	≤32	≤32	N/A	N/A	N/A
Oxacillin	Ox	4->4	≤0.25-0.5	N/A	N/A	N/A
Penicillin	P	0.5-2	0.25->8	N/A	N/A	N/A
Rifampin	Rif	≤1	≤1	N/A	N/A	N/A
Streptomycin Synergy Screen	StS	≤1000	N/A	>1000	N/A	N/A
Synercid	Syn	2->2	≤0.5-1	N/A	N/A	N/A
Tetracycline	Te	4->8	≤1	N/A	N/A	N/A
Tigecycline	Tgc	≤0.25	≤0.25	N/A	N/A	N/A
Trimethoprim-Sulfamethoxazole	T/S	≤0.5/9.5	≤0.5/9.5	N/A	N/A	N/A
Vancomycin	Va	1-4	0.5-2	N/A	N/A	N/A

1. Range = Expected value (µg/mL)

2. The range of some antimicrobics do not agree with the Acceptable Quality Control Ranges listed in the CLSI M100 Document.

3. For Turbidity inoculation method only. Gentamicin should be considered in control with the Prompt Inoculation System if gentamicin MIC is ≤1-2.

N/A = Not Applicable

WARRANTY STATEMENT

The system is covered by and subject to the provisions of the warranty included in your contractual agreement for the system or its reagents. The customer is responsible for routine preventive maintenance procedures. Repairs arising from the failure to perform these maintenance procedures at the indicated time intervals are made at the discretion of Beckman Coulter, and at the customer's expense.

TRADEMARKS

© 2025 Beckman Coulter, Inc. All rights reserved.

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

May be covered by one or more pat. – see www.beckmancoulter.com/patents.

Beckman Coulter, Inc.

250 S. Kraemer Blvd.
Brea, CA 92821 USA
Tel: +(1) 800-854-3633
www.beckmancoulter.com

11/2025